Features of responding T cells in cancer and chronic infection

Current Opinion in Immunology

Volumn 22, Issue 2, 2010, Pages 223-230

  Kim, Peter S ^a   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MELAN A; PD L1 BLOCKING ANTIBODY; UNCLASSIFIED DRUG; VACCINIA VACCINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLONAL ANERGY; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CANCER VACCINES; CHRONIC DISEASE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MICE; NEOPLASMS; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 77951258833     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2010.02.005     Document Type: Review

References (73)

1. Kaech S.M., Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2001, 2:415-422.
2. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003, 4:1191-1198.
3. Kaech S.M., Hemby S., Kersh E., Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
4. Wherry E.J., Teichgräber V., Becker T.C., Masopust D., Kaech S.M., Antia R., von Andrian U.H., Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4:225-234.
5. Wherry E.J., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004, 78:5535-5545.
6. Sarkar S., Kalia V., Haining W.N., Konieczny B.T., Subramaniam S., Ahmed R. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 2008, 205:625-640.
7. Oxenius A., Price D.A., Günthard H.F., Dawson S.J., Fagard C., Perrin L., Fischer M., Weber R., Plana M., García F., et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 2002, 99:13747-13752.
8. Markowitz M., Jin X., Hurley A., Simon V., Ramratnam B., Louie M., Deschenes G.R., Ramanathan M, Barsoum S., Vanderhoeven J., et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002, 186:634-643.
9. Lindenburg C.E., Stolte I., Langendam M.W., Miedema F., Williams I.G., Colebunders R., Weber J.N., Fisher M., Coutinho R.A. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002, 20:2343-2347.
10. Michel M.L.P.S., Brechot C, Tiollais P. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 2001, 19:2395-2399.
11. Mancini-Bourgine M., Fontaine H., Scott-Algara D., Pol S., Bréchot C., Michel M.L. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004, 40:874-882.
12. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-29.
13. Stauber R.E.S.V. Novel approaches for therapy of chronic hepatitis C. J Clin Virol 2006, 36:87-94.
14. Leroux-Roels G., Batens A.H., Desombere I., Van Den Steen B., Vander Stichele C., Maertens G., Hulstaert F. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005, 1.
15. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77:4911-4927.
16. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998, 75:5099-5107.
17. Wherry E.J., Barber D.L., Kaech S.M., Blattman J.N., Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A 2004, 101:16004-16009.
18. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., Subramaniam S., Blattman J.N., Barber D.L., Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
19. Barber D.L.W.E., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
20. Fuller M.J., Zajac A.J. Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 2003, 170:477-486.
21. van der Most R.G., Murali-Krishna K., Lanier J.G., Wherry E.J., Puglielli M.T., Blattman J.N., Sette A., Ahmed R. Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology 2003, 315:93-102.
22. Brooks D.G., Teyton L., Oldstone M.B., McGavern D.B. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol 2005, 10514-10527.
23. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994, 68:8056-8063.
24. Battegay M., Moskophidis D., Rahemtulla A., Hengartner H., Mak T.W., Zinkernagel R.M. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 1994, 68:4700-4704.
25. Keynan Y., Card C.M., McLaren P.J., Dawood M.R., Kasper K., Fowke K.R. The role of regulatory T cells in chronic and acute viral infections. Clin Infect Dis 2008, 46:1046-1052.
26. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A., Wherry E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10:29-37.
27. Day C.L., Kaufmann D.E., Kiepiela P. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 350-354.
28. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., Precopio M.L., Schacker T., Roederer M., Douek D.C., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292.
29. Trautmann L., Janbazian L., Chomont N., Said E.A., Gimmig S., Bessette B., Boulassel M.R., Delwart E., Sepulveda H., Balderas R., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
30. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., Ferrari C. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006, 80:11398-11403.
31. Penna A., Pilli M., Zerbini A., Orlandini A., Mezzadri S., Sacchelli L., Missale G., Ferrari C. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007, 45:588-601.
32. Radziewicz H., Ibegbu C.C., Fernandez M.L., Workowski K.A., Obideen K., Wehbi M., Hanson H.L., Steinberg J.P., Masopust D., Wherry E.J., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007, 81:2545-2553.
33. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., Laccabue D., Zerbini A., Cavalli A., Missale G., Bertoletti A., Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81:4215-4225.
34. Clerici M., Wynn T.A., Berzofsky J.A., Blatt S.P., Hendrix C.W., Sher A., Coffman R.L., Shearer G.M. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994, 173:1085-1091.
35. Ameglio F., Cordiali Fei P., Solmone M., Bonifati C., Prignano G., Giglio A., Caprilli F., Gentili G., Capobianchi M.R. Serum IL-10 levels in HIV-positive subjects: correlation with CDC stages. J Biol Regul Homeost Agents 1994, 8:48-52.
36. Accapezzato D., Francavilla V., Paroli M., Casciaro M., Chircu L.V., Cividini A., Abrignani S., Mondelli M.U., Barnaba V. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004, 113:963-972.
37. Woitas R.P., Petersen U., Moshage D., Brackmann H.H., Matz B., Sauerbruch T., Spengler U. HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J Gastroenterol 2002, 8:562-566.
38. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996, 24.
39. Rico M.A., Quiroga J.A., Subirá D., Castañón S., Esteban J.M., Pardo M., Carreño V. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 2001, 33:295-300.
40. Jones R.B., Ndhlovu L.C., Barbour J., Sheth P.M., Jha A.R., Long B.R., Wong J.C., Satkunarajah M., Schweneker M., Chapman J.M., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008, 205:2763-2779.
41. Golden-Mason L., Palmer B.E., Kassam N., Townshend-Bulson L., Livingston S., McMahon B.J., Castelblanco N., Kuchroo V., Gretch D.R., Rosen H.R. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 2009, 83:9122-9130.
42. Ju Y., Hou N., Zhang X.N., Zhao D., Liu Y., Wang J.J., Luan F., Shi W., Zhu F.L., Sun W.S., et al. Blockade of Tim-3 pathway ameliorates interferon-gamma production from hepatic CD8+ T cells in a mouse model of hepatitis B virus infection. Cell Mol Immunol 2009, 6:35-43.
43. Klebanoff C.A., Gattinoni L., Torabi-Parizi P., Kerstann K., Cardones A.R., Finkelstein S.E., Palmer D.C., Antony P.A., Hwang S.T., Rosenberg S.A., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005, 102:9571-9576.
44. Mueller K., Schweier O., Pircher H. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy. Eur J Immunol 2008, 38:2874-2885.
45. Gattinoni L., Zhong X.S., Palmer D.C., Ji Y., Hinrichs C.S., Yu Z., Wrzesinski C., Boni A., Cassard L., Garvin L.M., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 2009, 15:808-813.
46. Mumprecht S., Schürch C., Schwaller J., Solenthaler M., Ochsenbein A.F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009, 114:1528-1536.
47. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., Rosenberg S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
48. Fourcade J., Kudela P., Sun Z., Shen H., Land S.R., Lenzner D., Guillaume P., Luescher I.F., Sander C., Ferrone S., et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009, 182:5240-5249.
49. Gandhi M.K., Lambley E., Duraiswamy J., Dua U., Smith C., Elliott S., Gill D., Marlton P., Seymour J., Khanna R. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006, 108:2280-2289.
50. Grosso J.F., Kelleher C.C., Harris T.J., Maris C.H., Hipkiss E.L., De Marzo A., Anders R., Netto G., Getnet D., Bruno T.C., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007, 117:3383-3392.
51. Bennaceur K., Chapman J., Brikci-Nigassa L., Sanhadji K., Touraine J.L., Portoukalian J. Dendritic cells dysfunction in tumour environment. Cancer Lett 2008, 272:186-196.
52. Mellor A.L., Baban B., Chandler P., Marshall B., Jhaver K., Hansen A., Koni P.A., Iwashima M., Munn D.H. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol 2003, 171:1652-1655.
53. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838-3846.
54. Murdoch C, Muthana M, Coffelt SB, C.E. L: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631.
55. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., Pardoll D., Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998, 95:1178-1183.
56. Klein L., Trautman L., Psarras S., Schnell S., Siermann A., Liblau R., von Boehmer H., Khazaie K. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol 2003, 33:806-814.
57. Ha S.J., Mueller S.N., Wherry E.J., Barber D.L., Aubert R.D., Sharpe A.H., Freeman G.J., Ahmed R. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008, 205:543-555.
58. Brooks D.G., Lee A.M., Elsaesser H., McGavern D.B., Oldstone M.B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 2008, 205:533-541.
59. Ercolini A.M., Ladle B.H., Manning E.A., Pfannenstiel L.W., Armstrong T.D., Machiels J.P., Bieler J.G., Emens L.A., Reilly R.T., Jaffee E.M. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005, 201:1591-1602.
60. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116:1935-1945.
61. Li B., VanRoey M., Wang C., Chen T.H., Korman A., Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009, 15:1623-1634.
62. Curran M.A., Allison J.P. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 2009, 69:7747-7755.
63. Espenschied J., Lamont J., Longmate J., Pendas S., Wang Z., Diamond D.J., Ellenhorn J.D. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003, 170:3401-3407.
64. Gregor P.D., Wolchok J.D., Ferrone C.R., Buchinshky H., Guevara-Patiño J.A., Perales M.A., Mortazavi F., Bacich D., Heston W., Latouche J.B., et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004, 22:1700-1708.
65. Kudo-Saito C., Hodge J.W., Kwak H., Kim-Schulze S., Schlom J., Kaufman H.L. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 2006, 24:4975-4986.
66. Li Q., Iuchi T., Jure-Kunkel M.N., Chang A.E. Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci 2007, 3:455-462.
67. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S.E., Theoret M.R., Rosenberg S.A., Restifo N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005, 115:1616-1626.
68. Hinrichs C.S., Borman Z.A., Cassard L., Gattinoni L., Spolski R., Yu Z., Sanchez-Perez L., Muranski P., Kern S.J., Logun C., et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 2009, 106:17469-17474.
69. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009, 182:5891-5897.
70. Nakamoto N., Cho H., Shaked A., Olthoff K., Valiga M.E., Kaminski M., Gostick E., Price D.A., Freeman G.J., Wherry E.J., et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009, 5:1-13.
71. Homann D., Dummer W., Wolfe T., Rodrigo E., Theofilopoulos A.N., Oldstone M.B., von Herrath M.G. Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol 2006, 80:270-280.
72. Cecchinato V., Tryniszewska E., Ma Z.M., Vaccari M., Boasso A., Tsai W.P., Petrovas C., Fuchs D., Heraud J.M., Venzon D., et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 2008, 180:5439-5447.
73. Velu V., Titanji K., Zhu B., Husain S., Pladevega A., Lai L., Vanderford T.H., Chennareddi L., Silvestri G., Freeman G.J., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458:206-210.